Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oramed Pharmaceuticals Inc. (ORMP : NSDQ)

• Company Description    Oramed Pharmaceuticals, Inc. is a pharmaceutical company operating as a developer of oral drug delivery systems. The Company is developing orally ingestible insulin capsules for the treatment of diabetes as well as delivery solutions for other drugs and vaccines. Oramed Pharmaceuticals, Inc. is headquartered in Jerusalem, Israel. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $4.57 Daily Weekly Monthly 20 Day Moving Average: 865,255 shares Shares Outstanding: 38.56 (millions) Market Capitalization: $176.24 (millions) Beta: 2.02 52 Week High: $31.54 52 Week Low: $3.74 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -33.38% -27.28% 12 Week -56.72% -53.23% Year To Date -68.00% -62.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1185 AVENUE THIRD FLOOR - NEW YORK,NY 10036 USA ph: 844-967-2633 fax: 972-2566-0004 ir@oramed.com http://www.oramed.com

• General Corporate Information    Officers Nadav Kidron - President and Chief Executive Officer and Director David Silberman - Chief Financial Officer Aviad Friedman - Director Miriam Kidron - Director Arie Mayer - Director Peer Information Oramed Pharmaceuticals Inc. (BJCT) Oramed Pharmaceuticals Inc. (CADMQ) Oramed Pharmaceuticals Inc. (APNO) Oramed Pharmaceuticals Inc. (UPDC) Oramed Pharmaceuticals Inc. (IMTIQ) Oramed Pharmaceuticals Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 68403P203 SIC: 2834 Fiscal Year Fiscal Year End: August Last Reported Quarter: 11/01/21 Next Expected EPS Date: 05/17/22 Share - Related Items Shares Outstanding: 38.56 Most Recent Split Date: (:1) Beta: 2.02 Market Capitalization: $176.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.80 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/17/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.02 Price/Cash Flow: - Price / Sales: 65.20 EPS Growth vs. Year Ago Period: 4.35% vs. Previous Quarter: -4.76% Sales Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -1.32% ROE 02/28/22 - - 11/30/21 - -24.20 08/31/21 - -33.78 ROA 02/28/22 - - 11/30/21 - -21.70 08/31/21 - -28.59 Current Ratio 02/28/22 - - 11/30/21 - 19.89 08/31/21 - 14.27 Quick Ratio 02/28/22 - - 11/30/21 - 19.89 08/31/21 - 14.27 Operating Margin 02/28/22 - - 11/30/21 - -908.55 08/31/21 - -822.72 Net Margin 02/28/22 - - 11/30/21 - -908.55 08/31/21 - -822.72 Pre-Tax Margin 02/28/22 - - 11/30/21 - -944.03 08/31/21 - -850.50 Book Value 02/28/22 - - 11/30/21 - 4.48 08/31/21 - 3.58 Inventory Turnover 02/28/22 - - 11/30/21 - - 08/31/21 - - Debt-to-Equity 02/28/22 - - 11/30/21 - 0.00 08/31/21 - 0.00 Debt-to-Capital 02/28/22 - - 11/30/21 - 0.00 08/31/21 - 0.00

Powered by Zacks Investment Research ©